China's First Precision Microbiota Transplantation Solution Provider ChengGe Bio Secures Tens of Millions in Funding and Files for IPO

VCBeat (WeChat ID: vcbeat) has learned that TreatGut, China’s first company to provide comprehensive solutions for precision fecal microbiota transplantation (FMT) therapy, has completed its angel and Pre-A financing rounds, raising a total of tens of millions of yuan. The angel round was led by Guangzhou Institute of Respiratory Health Pharmaceutical Technology Co., Ltd., an enterprise within Academician Zhong Nanshan’s industry-academia-research cluster, with Yangpu Bay Innovation Business Incubator as a co-investor. The Pre-A round was led by Sanze Venture Capital, with Guanghua Venture Capital as a co-investor; the transaction has now been closed. This demonstrates domestic capital’s strong recognition of TreatGut’s FMT technology platform and its optimism about the explosive growth of the future microecology industry. Moving forward, TreatGut will further enhance its proprietary precision FMT therapy platform and accelerate the research and development of microecological drugs.

The human gut microbiota is referred to as the “second genome” of humans. Research on its relationship with human diseases and health has become one of the most cutting-edge and hottest research directions in the global scientific community today. According to the latest scientific and clinical studies, gut dysbiosis is directly associated with more than 50 diseases, including diabetes, obesity, cancer, and autism. Fecal microbiota transplantation (FMT), which treats diseases and improves health by modulating the human gut microbiota, is considered to have extremely broad prospects for clinical application. As of March 2019, over 200 clinical trial projects involving FMT had been registered on ClinicalTrials.gov. An increasing number of clinical studies have confirmed that FMT demonstrates significant clinical efficacy and a high safety profile, making it a new technology worthy of promotion and clinical recognition.

TreatGut, founded in 2016, is China’s first company to provide comprehensive solutions for precision fecal microbiota transplantation (FMT) therapy. It is a large-scale integrated biomedical technology enterprise with business spanning medical diagnostics, microecological therapy, microecological drug R&D, and big data mining in healthcare, and has established the world’s first platform for precision FMT therapy.（Precision Microbiota Transplantation Therapy，PMTT）。 

TreatGut’s core R&D team comprises scientists from prestigious domestic and international universities and renowned research institutions, including Harvard University, Michigan State University, The Chinese University of Hong Kong, and Xiamen University. With extensive experience in technological and clinical projects, the team has secured numerous patents both in China and abroad and maintains long-term exchanges with leading international technical teams. TreatGut’s Scientific Advisory Board consists of top-tier experts, including academicians of the Chinese Academy of Sciences and the U.S. National Academy of Sciences, as well as leading authorities in the field of microbiome science.

In just three years since its establishment, TreatGut has been recognized as a “National High-Tech Enterprise” and won the Gold Award in the National Finals of the 2019 China “Internet+” Innovation and Entrepreneurship Competition. The company has established the world’s first Precision Microbiota Transplantation Therapy (PMTT) platform. Leveraging PMTT-based transplantation technology, it is expanding the indications for microbiota transplantation. Building on the clinical and multi-omics data accumulated through the PMTT platform, TreatGut is developing microbiome-based therapeutics, creating an integrated service chain encompassing disease prevention, diagnosis, treatment, post-treatment assessment, and nutritional guidance targeting the gut microbiome, thereby achieving lifecycle health management centered on the microbiome.

TreatGut’s Precision Microbiota Transplantation Therapy (PMTT) platform features the following characteristics:

1. Established the world’s most stringent donor screening model to ensure donor quality;

2. Independently developed the most advanced microbiota separation and extraction instrument, capable of automated anaerobic operation and rapid extraction within 15 minutes;

3. Established the South China Microbiome Bank, currently the largest microbiome repository and R&D and treatment center for microecology;

4. Leveraging clinical data from thousands of patients who have undergone transplantation, and utilizing high-throughput sequencing platforms integrated with artificial intelligence and multi-omics big data analytics, we constructed the world’s first precision donor-recipient matching model, significantly improving the clinical efficacy of microbiota transplantation;

5. Achieved the preparation and clinical application of China's only liquid live-bacteria capsule, simplifying clinical procedures and eliminating the inconvenience associated with gastrointestinal endoscopy-based transplantation.

After years of technical promotion by the company, fecal microbiota transplantation (FMT) combined with PD-1 inhibitors for the treatment of triple-negative breast cancer has been granted a fund project by the National Cancer Center and has entered clinical research. Multiple nationwide multicenter clinical trials have also been launched sequentially. Currently, TreatGut has facilitated the approval of FMT billing codes by the Health Commissions and Medical Insurance Bureaus in multiple provinces. The number of partner hospitals has reached hundreds, covering 28 provinces and municipalities across China. Relying on the PMTT platform, TreatGut will continue to deepen its expertise in various disease areas, benefit more patients, and contribute modestly to the advancement of global medical science and technology.

As a pioneer in the industrialization of fecal microbiota transplantation in China, TreatGut is committed to collaborating with all like-minded partners to jointly advance the cause of human health!

Sanze Venture Capital is a council member of the Venture Capital Professional Committee of the China Investment Association and the Guangdong Venture Capital Promotion Association, as well as a founding institution and vice-presidential unit of the Hunan Equity Investment Association. It is one of the first professional institutions in China to qualify for fund management guided by capital injections from national finance and local governments, and among the first private equity investment management institutions approved by the China Securities Regulatory Commission.

Sanze Venture Capital, rooted in Hunan, serving China, and looking globally, efficiently integrates industrial and financial capital. With an open organizational structure and operational mechanism as its foundational guarantee, it provides personalized investment and operational value-added services to high-tech, high-growth small and medium-sized enterprises in China.

After more than a decade of growth and accumulation, Sanze Venture Capital has established a dual-driven investment and operational ecosystem for the pharmaceutical and healthcare industry, characterized by “investment-led” and “operation-supported” strategies, achieving breakthroughs and gaining recognition within the industry. The company’s fully developed industrial capital investment platform and resource integration service platform have been progressively refined.

Sanze Venture Capital boasts an outstanding team with deep industrial heritage, abundant industry resources, and comprehensive professional expertise. Leveraging a multidisciplinary core team spanning finance, industry, finance, law, and pharmaceuticals and healthcare, the company maintains long-term strategic partnerships with numerous domestic and international financial institutions, authoritative organizations, research institutes, industrial conglomerates, and government agencies.

Guanghua Venture Capital is an industrial fund jointly established by the Guangdong Provincial Government and Tsinghua University, serving as the industrialization and operational platform for the Tsinghua University Pearl River Delta Research Institute. Leveraging the R&D platform of the Tsinghua University Pearl River Delta Research Institute and supported by top-tier expert teams both domestically and internationally, Guanghua Venture Capital fully utilizes its own capital, social capital, and government industrial funds to maximize the combined advantages of financial instruments and investment incubation systems.

Guanghua Venture Capital’s business scope covers: (1) direct project investment; (2) fund fundraising and establishment; (3) fund management; (4) venture capital consulting; and (5) construction of innovative investment parks, among others. It focuses on the development of high-end equipment manufacturing (industrial robots, intelligent manufacturing equipment, precision machining and manufacturing); the transformation and upgrading of traditional industries (Internet-plus traditional manufacturing, high-end industrial design platforms); and the cultivation of strategic emerging industries (new materials, electronic information, biotechnology).

Guangzhou Institute of Respiratory Health Pharmaceutical Technology Co., Ltd. is the leading enterprise driving the industry-academia-research collaboration and technology transfer platform for the State Key Laboratory of Respiratory Disease and the National Clinical Research Center for Respiratory Disease, under the leadership of Academician Zhong Nanshan. Introduced into Guangzhou Science City in 2009 as one of the top ten key projects by the Guangzhou Development District, the company has established a 25,000-square-meter “State Key Laboratory of Respiratory Disease Industry-Academia-Research Base” in Guangzhou Science City and is currently constructing a 60,000-square-meter industrial base in the Foshan Nanhai High-Tech Development Zone. The company serves as the Science City Branch of the National Clinical Research Center for Respiratory Diseases and is the primary entity responsible for building the “Respiratory Health Industry Incubator” (under national-level incubation), the National University Science Park (incubation unit), and the Guangzhou Medical University Science Park (provincial-level). Focusing on industry-academia-research collaboration and incubation investment with Guangzhou Medical University and its affiliated hospitals, the company’s business activities include pharmaceutical R&D, project investment, incubator park management, incubation services, and medical health services.

Yangpu Bay Innovation Enterprise Incubator is a wholly-owned subsidiary of Guangzhou Improve Medical Instruments Co., Ltd. (Stock Code: 300030), a publicly listed company. Focusing on the medical and biopharmaceutical health sectors, it aims to provide services through an "investment + incubation + laboratory" model, facilitating the growth and development of high-tech industries and technological projects in the pharmaceutical, biological, and health fields.

Yangpu Bay boasts a robust management team and a professional R&D technical team, backed by extensive resources in the medical device industry and a specialized clinical diagnostic laboratory platform. With an elite team of experts continuously enhancing its social competitiveness and driving innovation, Yangpu Bay has established strategic cooperative incubators or partnerships in Guangzhou, Suzhou, Shanghai, Beijing, the United States, Israel, and multiple other regions worldwide. Currently, its incubation space in Guangzhou alone spans tens of thousands of square meters.

Yangpu Bay is dedicated to identifying and serving startups in the medical and healthcare sectors, enabling entrepreneurs to focus on innovation and R&D. It provides an incubation platform that integrates financial, industry, managerial, and environmental resources for resident enterprises, thereby facilitating the success and growth of next-generation startups and promoting the overall economic advancement of the medical and healthcare industries.